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www.cdatm.orgAbstractsObjective: To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention,
and reasons for not using dabigatran etexilate (DE) in Shanghai, China.
Methods: Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic data-
base. Use rate of antithrombotics and reasons for not using DE were extracted during follow-up. Patients' baseline characteristics,
recurrent ischemic stroke/TIA events and bleeding complications were analyzed.
Patients: From April 2012 to August 2014, 110 inpatients with NVAF-associated stroke were studied in our hospital. NVAF was
diagnosed by 12-lead electrocardiogram, 24 h Holter and echocardiography.
Results: Before introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38)
respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE
did not improve use of anticoagulants (P¼ 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two
(9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P ¼ 0.570).
Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P ¼ 1.000). The most
common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage
concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet
drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux)
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patients in Shanghai mainly because DE had not been covered by health insurance.
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Atrial fibrillation (AF) is the most common sus-
tained cardiac arrhythmia encountered in clinical
practice.1,2 It has been estimated that by 2050 there
will be 72 million AF patients in Asia,3 more than
double the combined number of patients from Europe
and the United States.4,5 There are almost 8 million
patients with AF in China6 and they have a 5-fold
higher risk of ischemic stroke. Over 20% of all
strokes can be attributed to AF and the mortality rate is
two times higher than that without AF.7 Embolic ce-
rebral infarction associated with AF can be prevented
by oral anticoagulants.8 Non-valvular atrial fibrillation
(NVAF) is a type of AF that does not associate with
rheumatic heart disease, artificial valve replacement,
and valve repair. The thromboembolism rate per 100
patient-years with NVAF was 4.8 in Danmark9 and 4.2
in the Middle East.10 According to recent guidelines,
NVAF patients with stroke risk should receive
Warfarin or novel oral anticoagulants therapy
(NOACs).11,12
The use rate of warfarin before introduction of
NOACs was 66.8% in America,13 65.2% in Australia,
63.9% in Europe, 39.7% in the AsiaePacific region,
37.2% in Latin America, 25.1% in Taiwan, China,14
and 16.2%e20.3% in the mainland of China.15,16
The low use rate of warfarin in China could be partly
explained by the limitation of warfarin; for example, a
long half-life period, a slow onset, a high plasma
protein binding rate, different metabolism rate among
individuals, drugedrug interactions and drugefood
interactions, and dosing frequency. Now that there are
four kinds of NOACs and many clinical trials, like RE-
LY,17 ROCKET-AF,18 ARISTOTLE19 and ENGAGE
AF-TIMI 48,20 that have all shown no inferiority and a
low bleeding rate, could they improve anticoagulation
for NVAF-associated stroke patients in China?
Dabigatran etexilate (DE) is the only kind of NOAC
that has been approved by the Chinese Food and
Drug Administration (April 2013). Since the use rate of
warfarin and the rate of INRs in the therapeutic rangeof 2.0e3.0 were low in theMainland of China,16 DE has
the possibility of overcoming the shortcomings of
warfarin. It has been three years sinceDEwas introduced
into the Chinese market; however, the use rate of DE in
Shanghai and its efficacy have not been reported yet.
This study recruited 110 patients with NVAF-
associated cerebral embolism in our stroke center
from April 2012 to August 2014 to investigate use of
antithrombotics and the influence of DE in anti-
coagulation therapy for NVAF patients.
Methods
Patients
From April 2012 to August 2014, 110 inpatients
with AF associated cardiogenic cerebral embolism
were prospectively registered in an electronic database
in our stroke center. AF was diagnosed by 12-lead
electrocardiogram or 24 h Holter and valvular AF
was excluded by echocardiography. The study has
obtained the consent of the ethics committee of our
hospital and all patients or their relatives signed con-
sent to participate in this prospective registration study.
The patients' treatment was decided by neurologists in
our hospital. After their discharge, their follow-ups
were done both in our hospital and in community
hospitals.
Study design
This was a single-center, registry-based study. Pa-
tients' data included gender, age, medical conditions,
prior medications, the results of clinical examinations,
and medications when they were discharged. We con-
ducted telephone follow-up from October 12th to
October 19th 2015. Questions included recurrent
ischemic stroke events, current anticoagulants or anti-
platelet drugs, reasons for not using DE, current INR if
using warfarin, and complications (bleeding). To pa-
tients enrolled before March 31st, 2013, their previous
medications were also questioned. We analyzed pa-
tients' baseline characteristics, recurrent ischemic
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rate of antithrombotics before and after introduction of
DE, bleeding complications, current INR if using
warfarin, and reasons for not using DE.
Statistical analysis
Categorical variables were reported as number or
percentage; continuous variables fitting a normal dis-
tribution were expressed as mean ± standard deviation
(SD). Statistical comparisons of the baseline charac-
teristics were performed using a Chi-square test,
analysis of variance (ANOVA), Student's t test or
Fisher's exact test as appropriate. Variables with a
P value <0.05 was considered statistically significant.
Data analysis was performed using IBM SPSS Statis-
tics 19 (SPSS, Inc., Chicago, Illinois, USA).
Results
Baseline characteristics
A total of 110 patients were included in the final
analysis. The mean age was 77.8 ± 9.8 years with a
female predominance (61.8%). The mean CHA2DS2-
Vasc score was 5.3 ± 1.3 and the mean HAS-BLED
score was 3.1 ± 0.9. Of all the 110 patients,
85 (77.3%) had persistent AF, 76 (69.1%) patients had
hypertension and 41 (37.3%) had diabetes mellitus.
More patients without antithrombotics had hyperten-
sion (90.5%, P ¼ 0.046) (Table 1).
Use rate of anticoagulants and antiplatelet drugs
Over a mean follow-up period of 23.0 ± 8.4 months
there was a drop-out rate of 6.0%, the use rate of DETable 1
Baseline characteristics of all the 110 patients.
Without antithrombotics
(n ¼ 21)
W
(
Female, % 15 (71.4) 2
Age, years 78.0 ± 9.8 7
Persistent AF, % 19 (90.0) 2
Hypertension, % 19 (90.5) 2
Diabetes mellitus, % 10 (47.6) 1
Severe renal disease, % 1 (4.8)
Abnormal hepatic function, % 7 (33.3)
NIHSS on admission 7.9 ± 6.9 6
CHA2DS2-Vasc 5.7 ± 1.0 5
HAS-BLED 3.4 ± 0.9 2
AF:atrial fibrillation; DE:dabigatran etexilate; Values are mean ± SD or n (%
2012 to August 31, 2014. Severe renal disease defined as CrCl <30 ml/minwas 9.1% (20% for 150 mg b.i.d. and 80% for 110 mg
b.i.d.), warfarin was 22.7% and antiplatelet agents was
49.1%. The mean INR of the warfarin group was
2.2± 0.3. In the antiplatelet agents group, the use rate of
Aspirin 100 mg q.d. was 28.2%, clopidogrel 75 mg q.d.
was 8.2%, Aspirin plus clopidogrel was 0.9%, and Tab
Cilostazol 100 mg b.i.d. (for those having hemorrhagic
transformation) was 11.8% (Fig. 1). Before introduction
of DE, the use rate of warfarin was 28.9% (11/38). After
the introduction of DE from April 2013, use rates of
warfarin and DE were 20.8% (15/72) and 12.5% (9/72)
respectively. DE did not improve use of anticoagulants
(P ¼ 0.639) (Table 2).
Reasons for not using DE
Among those who did not receive DE, financial
concerns ranked first with 61.0%, followed by incon-
venience of purchase (14.0%) and hemorrhage concerns
(11.0%). Six patients (6.0%) had severe renal disease
(creatinine clearance (CrCl) <30 ml/min) which was
contraindication for DE. Two patients (2.0%) died
during follow-up and drop-out rate was 6.0% (Fig. 2).
Complications
Of all the 10 patients using DE, only one patient had
dyspepsia and gastroesophageal reflux. Two patients
using warfarin found fecal occult blood so they
stopped warfarin and began to use antiplatelet drugs.
No bleeding event occurred in other groups.
Recurrent ischemic stroke events
Up to October 2015, there were 19 recurrent
ischemic stroke events. Recurrence rates of the threeith anticoagulants
n ¼ 35)
With antiplatelet drugs
(n ¼ 54)
P-value
2 (62.9) 31 (57.4) 0.527
7.2 ± 9.5 78.2 ± 10.6 0.904
9 (82.9) 38 (70.4) 0.120
1 (60.0) 35 (64.8) 0.046*
2 (34.3) 20 (37.0) 0.592
1 (2.9) 4 (7.4) 0.645
7 (20.0) 10 (18.5) 0.632
.3 ± 6.6 6.1 ± 5.4 0.523
.1 ± 1.4 5.2 ± 1.3 0.172
.9 ± 0.9 3.2 ± 1.0 0.098
). Baseline defined as date of atrial fibrillation. Data were from April 1,
.
Table 2
Use rate of antithrombotics and baseline characteristics comparison before and after introduction of DE.
Indices Before March 31st, 2013 (n ¼ 38) After April 1st, 2013 (n ¼ 72) P-value
Female, % 23(60.5) 45(62.5) 0.839
Age, years 78.2 ± 11.6 77.6 ± 8.8 0.077
Persistent AF, % 27(71.1) 59(81.9) 0.188
Hypertension, % 28(73.7) 47(65.3) 0.368
Diabetes mellitus, % 18(47.4) 24(33.3) 0.150
Severe renal disease, % 2(5.3) 4(5.6) 1.000
Abnormal hepatic function, % 12(31.6) 12(16.7) 0.088
NIHSS on admission 6.3 ± 5.7 6.6 ± 6.3 0.835
CHA2DS2-Vasc 5.4 ± 1.2 5.3 ± 1.3 0.571
HAS-BLED 3.2 ± 0.9 3.1 ± 0.9 0.589
With anticoagulants, % 11 (28.9) 24 (33.3) 0.639
Without antithrombotics, % 4 (10.5) 17 (23.6) 0.097
AF:atrial fibrillation; DE dabigatran etexilate.
Fig. 1. Use rates of anticoagulants and antiplatelet drugs in patients with non-valvular atrial fibrillation associated stroke in 2015. Tab Aspirin
100 mg q.d.; Tab clopidogrel 75 mg q.d.; Tab Cilostazol 100 mg b.i.d.; Tab Dabigatran etexilate 110 mg (80%) or 150 mg (20%) b.i.d.; for
warfarin group, the mean INR is 2.2 ± 0.3.
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18.5% (ten patients) for antiplatelet drugs and 9.5%
(two patients) for non-users (P ¼ 0.570). Furthermore,
recurrence rates were similar between the DE group
(20.0%) and the Warfarin group (20.0%, P ¼ 1.000).
No TIA occurred in any group.
Discussion
The use rate of warfarin in our stroke center was
22.7%, a little higher than that reported before
(16.3%e20.3%).15,16 However, compared with the use
rate (63.9%) in European countries, ours was far lower.
Chiang and his group21 compared Asians and non-
Asians from the RE-LY trial, the ROCKET AF trial
and the ARISTOTLE trial and pointed out that
warfarin was 'difficult' to use in Asians due to a higherrisk of bleeding, unstable INR and higher stroke rate.
However, excessive bleeding was not found in Asians
when NOACs were used, besides, the superiority of
NOACs to warfarin in reducing thromboembolism was
maintained; therefore NOACs are preferentially indi-
cated in Asians in terms of both efficacy and safety.
The use rate of DE was only 9.1% in our center. In
Europe, DE was the most frequently used alternative
option to warfarin and the ratio of warfarin and
NOACs was 1/1.5.22 According to our results, the ratio
of warfarin and NOACs was 2.5/1 in our center.
Although use rate of warfarin decreased after intro-
duction of DE, DE did not improve anticoagulation
therapy for NVAF patients (28.9% before introduction
and 33.3% after introduction, P ¼ 0.639). Since DE
was highly anticipated to take the place of Warfarin,
why was the use rate of DE still low in Shanghai?
Fig. 2. Reasons for not using Dabigatran etexilate in patients with non-valvular atrial fibrillation associated stroke in 2015. Follow-up time is
23.0 ± 8.4 months (mean ± SD), and drop-out rate is 6.0%.
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DE had not been covered by the health insurance in
Mainland of China. There are two dosages of DE,
150 mg for 25.1 Chinese yuan per pill and 110 mg for
19.8 Chinese yuan per pill, so a total of 50 Chinese
yuan per day will be the cost if a patient takes the
recommended dosage (150 mg b.i.d.), while only 0.5
Chinese yuan per day will cost if he chooses warfarin.
Most (80%) patients in our report who received anti-
coagulation therapy took DE 110 mg b.i.d. for econ-
omy and safety.
The other reason was inconvenience of purchase. DE
was introduced into the Chinese mainland market in
March 2013, and at the beginning only one pharmacy in
Shanghai provided DE. Moreover it also required an
appointment for registration. It takes about one week
from book to get the drugs. The majority of drugs in
mainland of China are not associated with this kind of
inconvenience. The problemmay be thatDE is a newand
expensive drug without the support of medicare.
Severe renal insufficiency was the contraindication
of DE, and six patients in our study did not receive
DE because their CrCl was less than 30 ml/min.
Instead, they were recommended for warfarin (one
patient) or antiplatelet therapy (five patients). In
addition, prescription instructions pointed out that
“clinical trials of AF related stroke excluded patients
with elevated liver enzymes >2ULN (the upper limit
of normal), so for this subgroup, treatment experience
is lacking and the use of this product is not recom-
mend”.23 Therefore in our clinical practice, werecommend liver-protection treatment when the pa-
tients' liver enzymes were higher than 2ULN. One
patient in our study received liver protection treatment
before use of DE and was normal after discharge.
Now he has taken DE for 25 months and his liver
function has remained normal.
The most common side effect of DE was dyspepsia
(13.2%/ year), followed by minor bleeding like skin
rash and pruritus (11.5%/ year). Other side effects
included gastroesophageal reflux, headache and gener-
alized discomfort (5.5%/ year).16 In our study, there
were no reported complications except for one patient
having dyspepsia and gastroesophageal reflux. Re-
ported bleeding events include a 4.1% per year inci-
dence of major gastrointestinal bleeding, intracranial
hemorrhage 0.5% per year and myocardial infarction of
0.5% per year in Hong Kong, China.24 One prospective
cohort study in Denmark showed that less intracranial
bleeding was seen with both DE doses and gastroin-
testinal bleeding was lower with DE at 110 mg b.i.d.
compared with warfarin.25 So 80% of patients received
DE at 110 mg b.i.d. since their average age was
80.6 ± 7.5 years, HAS-BLED score was 2.9 ± 0.7 and
DE was not covered by medicare. No bleeding event
occurred in DE patients according to our study.
Shanghai had a large aging population, and the inci-
dence of AF was higher with aging and frequent INR
detection was not ideal for most cases. If DE is covered
by medicare, low dose DE would be used extensively
because of its safety, convenience, and efficacy and
improved anticoagulation therapy for NVAF.
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effect on stroke prevention in AF patients26e28 and
patients with cardioembolic stroke, who were unwill-
ing or unable to take oral anticoagulants, had the
greatest risk of stroke recurrence.29 According to our
study, 19 patients underwent recurrent stroke (17.3%).
Recurrence rates of the three groups were 20.0% for
anticoagulants, 18.5% for antiplatelet drugs and 9.5%
for non-users (P ¼ 0.570) respectively. No superiority
was found between anticoagulant groups and other
groups; this could be because in our study, the number
of patients was relatively few.
In patients with NVAF and an increased risk of
stroke, prophylaxis, apixaban, dabigatran, and rivar-
oxaban are all cost-effective alternatives to
warfarin.30,31 Therefore, it is necessary to list DE into
Chinese medicare, thus enabling more patients to use
DE to prevent NVAF-associated stroke.
Conclusions
The use rate of anticoagulants was low (DE 9.1%,
Warfarin 22.7%) in NVAF-associated stroke in real
world practice according to our study; DE did not
significantly improve anticoagulation therapy for
NVAF patients in our center mainly because DE had
not been covered by Chinese medicare.
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